Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study

Abstract Background To verify the long-term (24-week) efficacy, safety, and tolerability of fremanezumab in real-life patients with high-frequency episodic migraine (HFEM: ≥ 8 days/month) or chronic migraine (CM: ≥ 15 days/month), and multiple preventive treatment failures. Methods This is a prospec...

Полное описание

Библиографические подробности

Главные авторы:	Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Paola Torelli, Cinzia Finocchi, Florindo d’Onofrio, Luigi d’Onofrio, Renata Rao, Stefano Messina, Laura Di Clemente, Angelo Ranieri, Massimo Autunno, Giuliano Sette, Bruno Colombo, Antonio Carnevale, Marco Aguggia, Miriam Tasillo, Francesco Zoroddu, Fabio Frediani, Massimo Filippi, Carlo Tomino, Stefania Proietti, Stefano Bonassi, for the FRIEND-Study Group
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2023-03-01
Серии:	The Journal of Headache and Pain
Предметы:	Fremanezumab Migraine treatment CGRP monoclonal antibody Real-world Long-term treatment
Online-ссылка:	https://doi.org/10.1186/s10194-023-01561-w
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!